United Therapeutics Strikes $525 Million Deal to Eliminate Ralinepag Royalties
Bitget2026/11/04 12:03- United Therapeutics entered a $525 million upfront agreement with Pfizer subsidiary Arena Pharmaceuticals to eliminate all ralinepag royalty obligations.
- The amendment removes a low double-digit royalty on net sales of all ralinepag formulations.
- A $250 million milestone remains payable upon the first US marketing approval of inhaled ralinepag for pulmonary arterial hypertension.
- A $150 million milestone remains payable upon first oral ralinepag marketing approval for any indication in Japan or specified European markets.
- Oral ralinepag’s application for pulmonary arterial hypertension remains under FDA review, with a June 24, 2027, user fee action date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. commercial crude oil inventories have declined for five consecutive weeks, while diesel inventories have fallen below 100 million barrels, reaching their lowest level since 2003.
EIA data shows that U.S. commercial crude oil inventories fell by 865,000 barrels last week to 409.8 million barrels, about 4% below the five-year seasonal average. The market had previously expected a decrease of around 200,000 barrels. Distillate fuel (including diesel and heating oil) inventories decreased by 3.6 million barrels to 99.3 million barrels, 13% below the five-year average. The market had previously expected a decline of only around 1 million barrels, making the actual reduction much greater than anticipated.
This Blockchain Is Abandoning Its Own Network—It Has Issued an Official Statement Regarding the Switch to Another Network
Crypto prices
More
